| International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Blood, The Journal of the American Society of Hematology 126 (3), 291-299, 2015 | 1295 | 2015 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1211 | 2016 |
| Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission AH Wei, H Döhner, C Pocock, P Montesinos, B Afanasyev, H Dombret, ... New England Journal of Medicine 383 (26), 2526-2537, 2020 | 323 | 2020 |
| Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening A Melk, W Kittikowit, I Sandhu, KM Halloran, P Grimm, BMW Schmidt, ... Kidney international 63 (6), 2134-2143, 2003 | 222 | 2003 |
| The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in … AH Wei, H Döhner, C Pocock, P Montesinos, B Afanasyev, H Dombret, ... Blood 134, LBA-3, 2019 | 117 | 2019 |
| Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for … P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... Blood 126 (23), 727, 2015 | 98 | 2015 |
| Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens JF Seymour, H Döhner, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... BMC cancer 17, 1-13, 2017 | 73 | 2017 |
| Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma PG Richardson, SK Kumar, T Masszi, N Grzasko, NJ Bahlis, M Hansson, ... Journal of Clinical Oncology 39 (22), 2430-2442, 2021 | 70 | 2021 |
| Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) CO Landgren, A Chari, YC Cohen, A Spencer, P Voorhees, JA Estell, ... Leukemia 34 (7), 1840-1852, 2020 | 69 | 2020 |
| Outcome of appendicectomy in children performed in paediatric surgery units compared with general surgery units S Tiboni, A Bhangu, NJ Hall, IG Panagiotopoulou, N Chatzizacharias, ... Journal of British Surgery 101 (6), 707-714, 2014 | 62 | 2014 |
| Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory … MV Mateos, T Masszi, N Grzasko, M Hansson, I Sandhu, L Pour, L Viterbo, ... haematologica 102 (10), 1767, 2017 | 54 | 2017 |
| Results of a phase 3, multicenter, randomized, open-label study of azacitidine (AZA) vs conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid … H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Haematologica 99, 788-789, 2014 | 43 | 2014 |
| A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND. 191 AE Hay, A Murugesan, AM DiPasquale, T Kouroukis, I Sandhu, V Kukreti, ... Leukemia & lymphoma 57 (6), 1463-1466, 2016 | 41 | 2016 |
| Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): CENTAURUS, a randomized, open-label, multicenter phase 2 study CC Hofmeister, A Chari, Y Cohen, A Spencer, PM Voorhees, J Estell, ... Blood 130, 510, 2017 | 39 | 2017 |
| Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre … MA Dimopoulos, PG Richardson, NJ Bahlis, S Grosicki, M Cavo, ... The Lancet Haematology 9 (6), e403-e414, 2022 | 30 | 2022 |
| Addressing heterogeneity of individual blood cancers: the need for single cell analysis LMP Michael P Chu, Jitra Kriangkum, Christopher P Venner, Irwindeep Sandhu ... Cell Biology and Toxicology, 1-15, 2016 | 26* | 2016 |
| Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, combines safely with pomalidomide and dexamethasone and shows promosing early results in relapsed-and-refractory … NS Raje, W Bensinger, CE Cole, S Lonial, S Jagannath, CE Arce-Lara, ... Blood 126 (23), 4228, 2015 | 25 | 2015 |
| PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED>= 65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR … H Dohner, A Symeonidis, MA Sanz, D Deeren, J Demeter, ... Haematologica 101, 185-186, 2016 | 24 | 2016 |
| Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus JM Brandwein, M Geddes, J Kassis, AK Kew, B Leber, T Nevill, M Sabloff, ... American Journal of Blood Research 3 (2), 141, 2013 | 24 | 2013 |
| Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines JM Brandwein, N Zhu, R Kumar, B Leber, M Sabloff, I Sandhu, J Kassis, ... American journal of blood research 7 (4), 30, 2017 | 23 | 2017 |
